Progenics Pharmaceuticals Inc (PGNX) - Financial and Strategic SWOT Analysis Review

October 2019 | 55 pages | ID: PE190089F93EN
GlobalData

Abstracts

Progenics Pharmaceuticals Inc (PGNX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – Analyst’s summarization of the company’s business strategy.
• SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
• Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
• Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Progenics Pharmaceuticals Inc (Progenics) is a biopharmaceutical company that develops and commercializes innovative targeted medicines to find, fight and follow cancer including therapeutic agents to treat cancer. Its products include Azedra, in treating unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma and Relistor in treatment of opioid-induced constipation. The company’s pipeline products include PyL (18F-DCFPyL) imaging agent for prostate cancer, 1095 (I 131 1095) and PSMA-TTC both of which are prostate specific membrane antigen (PSMA) being evaluated in treatment of metastatic prostate cancer. The company sells its products through distribution, co-promotion, co-marketing, or licensing arrangements with third parties for territories outside the U.S. Progenics is headquartered in New York, the US.

Progenics Pharmaceuticals Inc Key Recent Developments

Sep 18,2019: Velan launches consent solicitation to reconstitute the Progenics board with its five highly-qualified, independent director nominees
Sep 18,2019: Progenics confirms notice of preliminary consent solicitation by Velan Capital, L.P. despite repeated efforts by the company to reach a reasonable resolution
Aug 09,2019: Progenics Pharmaceuticals announces second quarter 2019 financial results and business update
Jul 08,2019: Progenics Pharmaceuticals strengthens management team with appointment of Huw Jones as Vice President, Commercial
Jul 08,2019: Progenics urges shareholders to vote today “FOR” the highly qualified director candidates on the WHITE Proxy Card

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

• The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

• The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

• Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

• Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

• Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

Progenics Pharmaceuticals Inc - Key Facts
Progenics Pharmaceuticals Inc - Key Employees
Progenics Pharmaceuticals Inc - Key Employee Biographies
Progenics Pharmaceuticals Inc - Major Products and Services
Progenics Pharmaceuticals Inc - History
Progenics Pharmaceuticals Inc - Company Statement
Progenics Pharmaceuticals Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
Progenics Pharmaceuticals Inc - Business Description
Progenics Pharmaceuticals Inc - SWOT Analysis
SWOT Analysis - Overview
Progenics Pharmaceuticals Inc - Strengths
Progenics Pharmaceuticals Inc - Weaknesses
Progenics Pharmaceuticals Inc - Opportunities
Progenics Pharmaceuticals Inc - Threats
Progenics Pharmaceuticals Inc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Progenics Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Progenics Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Progenics Pharmaceuticals Inc, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Sep 18, 2019: Velan launches consent solicitation to reconstitute the Progenics board with its five highly-qualified, independent director nominees
Sep 18, 2019: Progenics confirms notice of preliminary consent solicitation by Velan Capital, L.P. despite repeated efforts by the company to reach a reasonable resolution
Aug 09, 2019: Progenics Pharmaceuticals announces second quarter 2019 financial results and business update
Jul 08, 2019: Progenics Pharmaceuticals strengthens management team with appointment of Huw Jones as Vice President, Commercial
Jul 08, 2019: Progenics urges shareholders to vote today “FOR” the highly qualified director candidates on the WHITE Proxy Card
Jun 28, 2019: Velan clarifies interactions with Progenics Pharmaceuticals' board of directors
Jun 20, 2019: Velan calls on Progenics Pharmaceuticals' board to back up recent claims
May 09, 2019: Progenics Pharmaceuticals announces first quarter 2019 financial results and business update
May 06, 2019: Progenics Pharmaceuticals issues statement regarding Velan Capital
Mar 14, 2019: Progenics Pharmaceuticals announces fourth quarter and full-year 2018 financial results and business update

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Progenics Pharmaceuticals Inc, Key Facts
Progenics Pharmaceuticals Inc, Key Employees
Progenics Pharmaceuticals Inc, Key Employee Biographies
Progenics Pharmaceuticals Inc, Major Products and Services
Progenics Pharmaceuticals Inc, History
Progenics Pharmaceuticals Inc, Subsidiaries
Progenics Pharmaceuticals Inc, Key Competitors
Progenics Pharmaceuticals Inc, Ratios based on current share price
Progenics Pharmaceuticals Inc, Annual Ratios
Progenics Pharmaceuticals Inc, Annual Ratios (Cont...1)
Progenics Pharmaceuticals Inc, Annual Ratios (Cont...2)
Progenics Pharmaceuticals Inc, Interim Ratios
Progenics Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Progenics Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Progenics Pharmaceuticals Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Progenics Pharmaceuticals Inc, Performance Chart (2014 - 2018)
Progenics Pharmaceuticals Inc, Ratio Charts
Progenics Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Progenics Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019

COMPANIES MENTIONED

Shionogi & Co Ltd
Takeda Pharmaceutical Co Ltd
Jazz Pharmaceuticals Plc
Medivation Inc
AstraZeneca Plc
Nektar Therapeutics
Cubist Pharmaceuticals Holdings Inc
Aytu BioScience Inc
Janssen Biotech Inc
Blue Earth Diagnostics Ltd